(Q46681078)

English

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum

scientific article published in September 2005

Statements

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum (English)
0 references
0 references
European Organisation for Research and Treatment of Cancer

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit